KIAA1429 as a therapeutic target in osteosarcoma: challenging the linear ferroptosis pathway and evaluating translational hurdles.

The recent proposal by Xie et al. that KIAA1429 silencing ameliorates osteosarcoma progression primarily by promoting ferroptosis via the Nrf2/NQO1 axis offers a valuable yet potentially oversimplified mechanistic model. While this finding underscores the significant link between the m6A writer KIAA1429 and redox homeostasis, our critical appraisal identifies several conceptual oversights that challenge the directness and exclusivity of this pathway. The core vulnerability lies in attributing the complex phenotypic outcome of silencing a global RNA modifier to a single downstream axis, without conclusive genetic rescue evidence to establish Nrf2's indispensable role. Moreover, the pleiotropic nature of KIAA1429, which regulates a vast transcriptome encompassing other key ferroptosis regulators (e.g., GPX4, SLC7A11), is largely overlooked. The translational potential of targeting KIAA1429 is further questioned by the lack of assessment regarding on-target toxicities in normal cells, such as osteoblasts and mesenchymal stem cells, and the foreseeable resistance mechanisms via functional redundancy within the m6A machinery. This commentary urges a more nuanced interpretation of the data and highlights the formidable pharmacological challenges that must be overcome before KIAA1429 can be considered a viable therapeutic target.